

Oligo Synthesis : CEPs
Prices quoted are for single packs only. For multiples of the same product please request a quote. Some of Glen"sproductsarehazardousandmay be subject to additional shipping charges. Full product information is available onGlen Research"s website.
5"-Thiol-Modifier C6
5"-Thiol-Modifier C6
Glen Research
Catalogue No. | Description | Pack Size | Price | Qty |
|
---|---|---|---|---|---|
10-1926-02 | 5"-Thiol-Modifier C6 | 0.25g | £160.00£152.00Offer until : 31-Mar-2021Offer Code : GLEN5View Offer | Quantity | Add to Order |
10-1926-90 | 5"-Thiol-Modifier C6 | 100µmoles | £48.00£45.60Offer until : 31-Mar-2021Offer Code : GLEN5View Offer | Quantity | Add to Order |
Related products
5"-Thiol-Modifier C6
5"-Thiol-Modifier C6
Glen Research
5"-Thiol-Modifier C6 |
Catalog Number: 10-1926-xx
Description: 5"-Thiol-Modifier C6
S-Trityl-6-mercaptohexyl-1-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite | ||
Formula: C34H45N2O2PS | M.W.: 576.78 | F.W.: 196.20 |
Diluent: Anhydrous AcetonitrileAdd fresh diluent to product vial to recommended concentration and swirl vial occasionally over several minutes until product is completely dissolved.(Some oils may require between 5 and 10 minutes.) Use care to maintain anhydrous conditions.In case of transfer to alternate vial type, ensure recipient vial has been pre-dried. For more information, see http://www.glenres.com/Technical/TB_ABITransfer.pdf. |
Coupling: Standard coupling time.Use 0.02 M Iodine for Oxidation. |
Deprotection: The Trityl group protecting the sulfur must be removed with silver nitrate. See Technical Bulletin for details (Technical Bulletin). |
Storage: Freezer storage, -10 to -30°C, dry |
Stability in Solution: 2-3 days |
The disulfide thiol modifier may be used for introducing 3’-or 5’-thiol linkages. Dithiol Phosphoramidite (DTPA) is a disulfide-containingmodifier designed to functionalize synthetic DNA or RNA with multiple thiolgroups and can be incorporated at any position of the oligonucleotide. Each DTPAaddition leads to two thiol groups. This modifier was designed for optimaltethering of oligonucleotides to a gold surface but it can also be used formultiple reactions with maleimides and other thiol-specific derivatives.5’-Carboxy-Modifier C10 is a unique linker designed to be added at the terminusof an oligonucleotide synthesis. It generates an activated carboxylic acidN-hydroxysuccinimide (NHS) ester suitable for immediate conjugation on thesynthesis column with molecules containing a primary amine, resulting in astable amide linkage. PC Amino-Modifier is a photocleavable C6 amino-modifier,part of our line of photocleavable (PC) modifiers.
5’-AminoOxy-Modifier 11 is based on a tetraethylene glycol linkage forimproved solubility and for reducing the potential negative impact onhybridization of the oligo. The oxime formed from the reaction of alkyloxyamineswith aldehydes creates a stable covalent bond. In comparison, the imine formedby the conjugation of primary amines with aldehydes is not stable to acidic orbasic conditions and requires subsequent reduction with borohydride to formstable amine conjugates. 5’-Maleimide Modifier Phosphoramidite, developed at theUniversity of Barcelona, incorporates a maleimide cycloadduct that is stable toammonium hydroxide at room temperature. This phosphoramidite can be incorporatedinto DNA and RNA with both phosphate and phosphorothioate linkages. Aretro–Diels-Alder reaction deprotects the maleimide immediately prior toconjugation.
If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200
5"-Thiol-Modifier C6
5"-Thiol-Modifier C6
Glen Research
MSDS
If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200
5"-Thiol-Modifier C6
5"-Thiol-Modifier C6
Glen Research
Frequently Asked Technical Question
QUESTION: What is the "T" in the structure of thiol-modifier C6?
RESPONSE:"T" is short for trityl or triphenylmethyl.This group is not significantly acid labile and requires an oxidative cleavage with silver nitrate to remove it.It is also susceptible to oxidative cleavage with the iodine oxidizer and, for maximum yield, the iodine concentration in that oxidizer should be 0.02M, which is now virtually standard.
REFERENCE(S):Glen Research User Guide to Modification and Labelling, 1999, 24.
QUESTION: What is the best method to make peptide-oligonucleotide conjugates?
RESPONSE:It would seem that the best method to make peptide-oligo conjugates would be to use Fmoc chemistry and synthesize the peptide off an oligo synthesized on amino-CPG.However, deprotection of peptides synthesized using Fmoc chemistry requires 50% TFA and t-boc synthesized peptides require HF both ofwhich would severely damage if not completely hydrolyze the oligo.
The best and most straight foward method is to use a heterobifunctional crosslinking reagent to link a synthetic peptide, containing an N-terminal lysine, to a 5"-Thiol modified oligo or conversely a 5"-amino modified oligo to a cysteine containing peptide .A good crosslinking reagent is N-Maleimido-6-aminocaproyl- (2"-nitro,4"-sulfonic acid)-phenyl ester . Na (mal-sac-HNSA) from Bachem Bioscience (cat. # Q-1615).Reaction of this crosslinker with an amino group releases the dianion phenolate, 1-hydroxy-2-nitro -4-benzene sulfonic acid a yellow chromophore.The chromophore allows both quantitation of the coupling reaction as well as act as an aid in monitoring the seperation of "activated peptide" from free crosslinking reagent using gel filtration.
Method A: Couple Peptide Amine To Oligo Thiol (Note peptide MW must be > 5,000 to be excluded from desalting column).This method best for oligo-enzyme conjugation.
Step 1:Synthesize a peptide with an N-terminal, or internal, lysine (The epsilon amino group is more reactive than an alpha amino group).
Step 2:Synthesize an oligonucleotide with a 5" Thiol group.
Step 3:React peptide with excess mal-sac-HNSA (pH 7.5 Sodium phosphate)
Step 4:Seperation of peptide-mal-sac conjugate from free crosslinker and buffer exchange (pH 6.0 Sodium phosphate) using a gel filtration column (Glen Gel-Pak™ or eq.).Note peptide must be large enough to seperate from the free linker which can be visualized as a yellow band.Do not collect yellow band with peptide.
Step 5:Activate thiol modified oligo, desalt and buffer exchange (pH 6 Sodium phosphate) on Glen Gel-Pak™ column.
Step 6:React acitvated peptide with Thiol modified oligo.
Step 7:Purify Peptide-Oligo conjugate by ion exchange chromatography on Nucleogen DEAE-500-10 or eq.Elution order: free peptide, peptide-oligo, free oligo.
Method B: Couple Oligo Amine To Peptide Cysteine (Note oligos > 15mers are excluded from desalting column).Use above procedure switching oligo for peptide.
Step 1:Synthesize a peptide with an N-terminal, or internal, cysteine
Step 2:Synthesize an oligonucleotide with a 5" amino modifier.
Step 3:Purify oligo Trityl-on by RP HPLC or cartridge.
Step 4:React oligo with excess mal-sac-HNSA (pH 7.5 Sodium phosphate)
Step 5:Seperation of oligo-mal-sac conjugate from free crosslinker and buffer exchange (pH 6 Sodium phosphate) using a gel filtration column (Glen Gel-Pak™ or eq.).Note oligo must be large enough to seperate from the free linker which can be visualized as a yellow band.Do not collect yellow band with oligo.
Step 6:Dissolve peptide in pH 6.0 Sodium phosphate buffer and react with activated oligo.
Step 7:Purify Peptide-Oligo conjugate by ion exchange chromatography on Nucleogen DEAE-500-10 or eq.Elution order: free peptide, peptide-oligo, free oligo.
QUESTION: What is the best method to deprotected thio-modified oligos (10-1926)?
RESPONSE:The trityl group used to protect the thiol is not acid labile and therefore can not be removed on a DNA synthesizer using
the normal acid deprotection. Cleavage of the oligonucleotide from the support and removal of the base-protecting groups are carried out with ammonium hydroxide in the normal manner. If purification is desired, it should be done before removing the trityl group. The presence of the trityl group allows standard trityl-on reverse phase (RP) purification techniques to be used.
Final deblocking of the oligonucleotide involves cleavage of the trityl-sulfur bond. This is accomplished by oxidation with silver nitrate with the excess silver nitrate being precipitated with dithiothreitol (DTT). Excess DTT can be removed by extraction with ethyl acetate, by desalting or by ethanol precipitation.
Procedure
1. Deprotect with ammonium hydroxide in the normal manner.
2. Purify the trityl containing oligonucleotide by HPLC or Poly-Pak cartridge.
3. Evaporate the product solution to dryness.
4. Suspend the product in 0.1M triethylammonium acetate (TEAA), pH6.5 at a concentration of ~100 A260 units/mL.
5. Add 0.15 volumes of 1M aqueous silver nitrate solution, mix thoroughly, and react at room temperature for 30 min.
6. Add 0.20 volumes of 1M aqueous DTT solution, mix thoroughly, and leave at room temperature for 5 minutes.
7. Centrifuge the suspension to remove the silver DTT complex. Remove the supernatant. Wash the precipitate with 1 volume of 0.1M TEAA. Centrifuge and combine the supernatant with the first volume.
8. Proceed directly to the conjugation reaction. (If desired, excess DTT can be removed by ethyl acetate extraction. The free thiol oligonucleotide must be stored under an inert atmosphere to avoid oxidative dimerization to the disulfide.)
If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200
5"-Thiol-Modifier C6
5"-Thiol-Modifier C6
Glen Research
Technical notes click here
DILUTION/COUPLING DATA
The table below shows pack size data and, for solutions, dilutions and approximate couplings based on normal priming procedures.
ABI 392/394 | |||||||||
Cat.No. | PackSize | Grams/Pack | 0.1M Dil.(mL) | LV40 | LV200 | 40nm | 0.2µm | 1µm | 10µm |
Approximate Number of Additions | |||||||||
10-1926-02 | 0.25grams | .25grams | 4.33 | 131 | 78.6 | 49.13 | 35.73 | 26.2 | 6.55 |
10-1926-90 | 100µmoles | .058grams | 1 | 20 | 12 | 7.5 | 5.45 | 4 | 1 |
Expedite | |||||||||
Cat.No. | PackSize | Grams/Pack | Dilution(mL) | Molarity | 50nm | 0.2µm | 1µm | 15µm | |
Approximate Number of Additions | |||||||||
10-1926-02 | 0.25grams | .25grams | 6.47 | .07 | 123 | 76.88 | 55.91 | 7.69 | |
10-1926-90 | 100µmoles | .058grams | 1.5 | .07 | 23.6 | 14.75 | 10.73 | 1.48 | |
Beckman | |||||||||
Cat.No. | PackSize | Grams/Pack | Dilution(mL) | Molarity | 30nm | 200nm | 1000nm | ||
Approximate Number of Additions | |||||||||
10-1926-02 | 0.25grams | .25grams | 6.47 | .07 | 124.6 | 77.88 | 56.64 | ||
10-1926-90 | 100µmoles | .058grams | 1.5 | .07 | 25.2 | 15.75 | 11.45 |
If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200
AthensResearch&Technology公司位于美国乔治亚州雅典市,从1986年以来一直致力于纯化高纯度,高活性的人类蛋白质和开发这些蛋白的多克隆抗血清。我们的常规产品包括丝氨酸蛋白酶、蛋白酶抑制剂、中性粒细胞酶、载脂蛋白、脂蛋白,血小板蛋白、转铁蛋白、免疫球蛋白等。二十年多年来,世界各地的研究人员都在使用我们公司的产品。在炎症、冠状动脉疾病、自身免疫性疾病、癌症、老年痴呆症等等研究的主要科学出版物中都能看到引用我们公司的产品。我们提供优质,可靠的产品和出色的客户服务。我们期待着您的业务。如果需要定制研究服务,AthensResearch&Technology公司能够根据您的项目要求提供无与伦比的试剂。
公司主要产品:一、凝血因子相关系列产品:包括多款从人血浆、血小板中分离纯化的凝血因子相关蛋白。二、酶及抑制剂系列产品:包括多款从人血浆、红细胞分离纯化的a-抗糜蛋白酶、a1/2抗胰蛋白酶、抗凝血酶、C1酯酶抑制因子、Calpain-1等酶及其抑制剂产品。三、免疫球蛋白系列产品:包括多款从人血浆、骨髓瘤、初乳以及狗和小鼠血浆中分离纯化的免疫球蛋白产品。四、脂蛋白及载脂蛋白系列产品:包括包括多款从人血浆中分离纯化的载脂蛋白及脂蛋白(高密度、中等密度、低密度、极低密度脂蛋白)产品。五、低内毒素蛋白系列产品:包括多款适宜于细胞培养的低内毒素脂蛋白、免疫球蛋白及转铁蛋白产品。六、乳蛋白系列产品:包括从人乳中分离纯化的乳白蛋白、乳铁传递蛋白及分泌型免疫球蛋白A。七、中性粒细胞源蛋白系列产品:包括多款纯化分离自人中性粒细胞的Azurocidin 、CathepsinG及Lactoferrin等蛋白产品。八、血小板相关系列产品:包括纯化分离自人血小板的血小板因子4及凝血酶致敏蛋白。九、转铁蛋白及脱铁转铁蛋白(APOTRANSFERRINS)系列产品:包括多款纯化分离自人、大小鼠、狗及食蟹猴血浆中的转铁蛋白/脱铁转铁蛋白,可应用于细胞或组织培养。十、抗体系列产品:包括多款兔、大鼠、羊源的多克隆抗体产品。
ebiomall.com







